TruScreen Group Limited Ordinary Shares
TRU.NZXHealth Care
TruScreen's development began in the late 1980s under the guidance of leading medical academics from Sydney University. TruScreen offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and wellbeing of women around the world. Professor Coppleson, an international leader in colposcopy and cervical cancer, sought to establish objective technology that could improve on the conventional Pap test, which has limitations in population based screening due to its subjective nature and its need of laboratory facilities and qualified personnel. Dr. Reid believed that it should be possible to distinguish between normal and abnormal tissue by measuring changes in physical properties, such as electrical potential. After almost 15 years of intensive R&D, the TruScreen 'Opto Electrical' Technology for the detection of cancerous cells is now being made commercially available to global markets. As the TruScreen technology is at the forefront of the development of objective opto-electric tissue differentiation it enjoys significant patent protection which is of great interest throughout the globe. Following the restructuring of the business, TruScreen Pty Ltd, a subsidiary company of TruScreen Group Ltd (NZ), was formed in October 2013 to hold all TruScreen assets, including IP, and to act as the operations heart of the TruScreen business. The board and executive team combine experience and commercial ideas and strategies which we believe are both essential to and sufficient for the success of TruScreen globally. TruScreen is a compliance listing there will be no new shares issued upon listing. TruScreen is expected to commence trading on the NZX Alternative Board on 12 November 2014.
Market Data
$0.018
-0.1%$13.5M
-4.7x
$-0.004
0.00%
-0.4%
Latest Earnings
TruScreen Preliminary Final Results
29 May 2026
TruScreen Group Limited reported FY2026 revenue from continuing operations of NZ$2.43M, up 42% year-on-year, driven by expansion into new markets including India and Indonesia. Despite the strong top-line growth, the net loss was largely unchanged at NZ$2.25M (vs NZ$2.24M in FY2025) as higher gross margins (31.5% vs 30.1%) were offset by increased overhead and marketing costs. The company raised ~NZ$4M in equity during the year and is pursuing large public screening programme opportunities, including three UNITAID proposals covering 14 high-burden countries. Key points: Revenue from continuing operations grew 42% YOY to NZ$2.43M, with sales achieved across a broader range of countries including first sales in India and Indonesia; Gross margin improved to 31.5% from 30.1% in FY2025, with further improvement expected in FY2027; Launch of 5-year programme to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam
Recent Announcements
TruScreen Preliminary Final Results
TruScreen Group Limited reported FY2026 revenue from continuing operations of NZ$2.43M, up 42% year-on-year, driven by expansion into new markets including India and Indonesia. Despite the strong top-line growth, the net loss was largely unchanged at NZ$2.25M (vs NZ$2.24M in FY2025) as higher gross margins (31.5% vs 30.1%) were offset by increased overhead and marketing costs. The company raised ~NZ$4M in equity during the year and is pursuing large public screening programme opportunities, including three UNITAID proposals covering 14 high-burden countries. Key points: Revenue from continuing operations grew 42% YOY to NZ$2.43M, with sales achieved across a broader range of countries including first sales in India and Indonesia; Gross margin improved to 31.5% from 30.1% in FY2025, with further improvement expected in FY2027; Launch of 5-year programme to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam
TruScreen Appoints Uzbekistan Distributor
TruScreen Group Limited appointed Albatros Health Care LLC as its distributor in Uzbekistan with USD740,000 (NZD1.26m) revenue potential through 2028, and commenced a pilot clinical study of approximately 600 participants in Tashkent to validate its AI-enabled cervical cancer screening technology for public and private healthcare use.
TRU – Trading to resume at market open
NZX has announced that trading in TruScreen Group Limited (TRU) equity securities will resume following a market announcement by the company on Monday, 25 May 2026.
TruScreen Completes Oversubscribed Placement
TruScreen Group Limited completed an oversubscribed placement of approximately 130 million shares at NZ$0.014/A$0.012 per share, raising approximately NZ$1.82m/A$1.52m before costs, with 110 million shares to be issued on 1 June 2026 and 20 million shares subject to shareholder approval in July 2026, alongside a concurrent renounceable rights issue and free attaching options.
TruScreen Announces Opening of $2.9 million Capital Raise
TruScreen Group Limited (NZX/ASX: TRU) announced a NZ$2.943 million capital raise comprising a NZ$1 million placement at NZ$0.014 per share (with attaching options) and a 1-for-5 rights offer at NZ$0.013 per share to eligible shareholders in New Zealand and Australia. The company, which achieved 42% YOY product sales growth and recently entered markets in India and Indonesia, intends to use proceeds for regulatory compliance, market expansion, clinical evidence development, and working capital.
TruScreen Group Ltd (“TRU”) – Trading Halt of Securities
TruScreen Group Limited (NZX/ASX: TRU) requested a trading halt effective pre-market open on 21 May 2026 to conduct a capital raising comprising a placement of up to NZ$1 million and a pro-rata rights issue of up to NZ$1.943 million, with trading expected to resume by 25 May 2026 or upon completion announcement.
Change of Auditors
TruScreen Group Limited (NZX/ASX: TRU) announced that Hall Chadwick NZ Limited has resigned as auditors, with Mr. Vinay Sheoran of Hall Chadwick (NSW) Limited becoming the new registered audit provider effective immediately, reflecting the Company's substantial operations in New South Wales.
Tru Partners with LSUTH Gates Foundation Grant Application
TruScreen Group Limited has partnered with Lagos State University Teaching Hospital (LASUTH) to submit a US$300,000 grant application to the Bill & Melinda Gates Foundation for a two-year study validating TruScreen's AI-enabled cervical cancer screening device in Nigeria, targeting 500-1,500 women with results expected within six months.
FY 31 March 2026 Revenue and Results Guidance Achieved
TruScreen Group confirmed it achieved its FY2026 (year ending 31 March 2026) guidance, with unaudited product sales revenue of approximately NZ$2.4M (+41% on FY2025) and total revenue of approximately NZ$2.8M (+29% on FY2025), slightly exceeding prior guidance. The company is expected to report a net loss of approximately NZ$2.2M, similar to FY2025, as it continues investing in market expansion across Uzbekistan, India, Indonesia, and selected African markets. A significant potential catalyst exists with three UNITAID funding applications submitted for programmes worth up to US$57.3M over three years, with outcomes expected around November 2026. Key points: Total revenue of ~NZ$2.8M slightly exceeded prior guidance and grew ~29% on FY2025; Product sales revenue of ~NZ$2.4M grew 41% on FY2025, reflecting strong underlying commercial momentum; Revenue now spread across a wider number of countries, indicating geographic diversification and broadening distributor network
Submits Proposals for Substantial Screening Programmes
TruScreen Group Limited (NZX/ASX: TRU) has submitted three proposals to UNITAID for cervical cancer elimination programmes across 14 high-burden countries in Africa, Asia-Pacific, and Latin America, with potential total funding of US$57.3 million and estimated revenue to TruScreen of up to US$18.4 million over three years, with results expected around November 2026.
Get real-time alerts for TRU
Receive AI-powered earnings summaries and instant notifications when TruScreen Group Limited Ordinary Shares releases results.
Register Free